Inhibition of salivary glands to reduce uptake of radioactive Iodine

Inhibition of salivary glands to reduce uptake of radioactive Iodine - Inhibition of Salivary glands for radioactive Iodine

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON46303

Enrollment

Registered

2019-01-11

Start date

2018-09-01

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iodine accumulation in salivary glands. Iodine biodistribution

Interventions

Pharmaceutical intervention is one intramuscular administration of 0.4 mg GPB (conditionally 0.2 mg after the first 5 patients). Diagnostic interventions are two Iodine-123 imaging procedures (one w

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - In follow-up after treatment for thyroid carcinoma - Received only one treatment with Iodine-131 - Currently no signs of recurrence

Exclusion criteria

Exclusion criteria: - Age

Design outcomes

Primary

Measure	Time frame
The primary parameter is the total quantified uptake of Iodine-123 on planar scintigraphy in all macroscopic salivary glands together (with and without GPB) measured at 4h after administration.	—

Secondary

Measure	Time frame
Secondary parameters are the uptake in salivary glands at 24h, uptake in stomach and bowels, and uptake in other normal tissues throughout the body.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)